Ticagrelor Improves Peripheral Arterial Function in Acute Coronary Syndrome Patients Relationship With Adenosine Plasma Level
Ticagrelor, a P2Y 12 receptor antagonist, significantly reduces the incidence of major cardiovascular events in acute coronary syndrome (ACS) compared with standard treatment with clopidogrel (1) . It has been remains poorly investigated. This study aimed to determine whether the increase in APL achieved with ticagrelor might improve endothelial dysfunction in primary ACS patients. dose followed by 90 mg twice daily) or clopidogrel (600-mg loading dose followed by 75 mg/day). In addition, all patients received 250 mg of ticagrelor followed by 75 mg of aspirin daily. Exclusion criteria were New York Heart Association functional class III or higher, cardiac arrest, contraindications to antiplatelet therapy, treatment with a P2Y 12 -adenosine diphosphate receptor antagonist for <1 month, a platelet count <100 g/l, a history of bleeding diathesis, a history of stroke, recent surgery (preceding month), use of a medication known to interfere with ticagrelor, and bradycardia. Blood samples (3 ml) were collected under basal conditions (just before the primary loading dose) and after 30 days of treatment.
APL was measured as previously described using high-pressure liquid chromatography (2) .
To assess MiD, we performed digital peripheral suggested that this benefit effect may be accounted artery tonometry at the same time to evaluate for by its pleiotropic properties via a purinergic the reactive hyperemia index (RHI). Endothelial mechanism. Indeed, ticagrelor increases the endodysfunction was suspected if the RHI was <1.67. The genous adenosine plasma level (APL) via red blood methodology has been previously described (3).
cell uptake inhibition in primary ACS patients Briefly, each recording consisted of 5 min of baseline compared with clopidogrel (2). However, the link measurements, 5 min of occlusion measurements, and between these "pleiotropic" properties and the then 5 min of post-occlusion measurements (hyperimprovement in microvascular dysfunction (MiD) emic period) (3). The RHI was defined as the ratio of the digital pulse volume during reactive hyperemia to that observed at baseline. Adverse cardiovascular events were recorded.
Under basal conditions, all the patients had MiD
We prospectively randomized 60 primary ACS (RHI <1.67; mean, 1.37 0.12). The APL ( Figure 1A ) and patients to receive ticagrelor (180-mg loading RHI ( Figure 1B) did not differ between the 2 groups of patients. At day 30, the APL increased significantly only in the ticagrelor group ( Figure 1A) . The APL was more than 2-fold higher in patients taking ticagrelor Finally, our study demonstrates a correlation between the increase in the APL and improvement in the RHI, but whether this increase in the APL has a direct effect on endothelial function remains to be established.
